Advertisement

Drug Investigation

, Volume 7, Issue 5, pp 282–287 | Cite as

Pharmacokinetics of Zidovudine and Metabolites in a Patient with HIV-Associated Nephropathy and Severe Renal Impairment

  • D. M. Burger
  • P. L. Meenhorst
  • J. W. Mulder
  • C. H. W. Koks
  • A. Bult
  • J. H. Beijnen
Case Report

Keywords

Human Immunodeficiency Virus Zidovudine Drug Invest Mean Corpuscular Volume Severe Renal Impairment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Blum MR, Liao SHT, Good SS, De Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. American Journal of Medicine 85 (Suppl. 2A): 189–194, 1988PubMedGoogle Scholar
  2. Burger DM, Meenhorst PL, Koks CHW, Beijnen JH. Drug interactions with zidovudine. AIDS 7: 445–460, 1993aPubMedCrossRefGoogle Scholar
  3. Burger DM, Rosing H, Koopman FJ, et al. Determination of 3′-amino-3′-deoxythymidine, a cytotoxic metabolite of 3′-azido-3′-deoxythymidine, in human plasma by ion-pair high performance liquid chromatography. Journal of Chromatography (Biomedical Applications) 622: 235–242, 1993bCrossRefGoogle Scholar
  4. Cretton EM, Xie M-Y, Bevan RJ, Goudgaon NM, Schinazi RF, et al. Catabolism of 3′-azido-3′-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3′-amino-3′-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Molecular Pharmacology 39: 258–266, 1991PubMedGoogle Scholar
  5. Deray G, Diquet B, Martinez F, Vidal AM, Petitclerc T, et al. Pharmacokinetics of zidovudine in a patient on maintenance haemodialysis [Letter]. New England Journal of Medicine 319: 1606–1607, 1988PubMedCrossRefGoogle Scholar
  6. Ersley AJ. Erythropoietin. New England Journal of Medicine 324: 1339–1344, 1991CrossRefGoogle Scholar
  7. Gallicano KD, Tobe S, Sahai J, McGilveray IJ, Cameron DW, et al. Pharmacokinetics of single and chronic dose zidovudine in two HIV-positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Journal of Acquired Immune Deficiency Syndromes 5: 242–250, 1992PubMedGoogle Scholar
  8. Gibaldi M. Biopharmaceutics and clinical pharmacokinetics. 4th Edition, pp. 14–23, Lea & Febiger, Philadelphia, 1991Google Scholar
  9. Glassock RJ (moderator). Human immunodeficiency virus (HIV) infection and the kidney. Annals of Internal Medicine 112: 35–49, 1990PubMedGoogle Scholar
  10. Henry DH, Beall GN, Benson CA, Carey J, Cone LA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. Annals of Internal Medicine 117: 739–748, 1992PubMedGoogle Scholar
  11. Howe JL, Back DJ, Colbert J. Extrahepatic metabolism of zidovudine. British Journal of Clinical Pharmacology 33: 190–192, 1992PubMedCrossRefGoogle Scholar
  12. Klecker RW, Collins JM, Yarchoan R, Thomas R, Jenkins JF, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clinical Pharmacology and Therapeutics 41: 407–412, 1987PubMedCrossRefGoogle Scholar
  13. Kremer D, Munar MY, Kohlhepp SJ, Swan SK, Stinnett EA, et al. Zidovudine pharmacokinetics in five HIV seronegative patients undergoing continuous ambulatory peritoneal dialysis. Pharmacotherapy 21: 56–60, 1992Google Scholar
  14. McLeod GX, Hammer SM. Zidovudine: five years later. Annals of Internal Medicine 117: 487–501, 1992PubMedGoogle Scholar
  15. Michel C, Dosquet P, Ronco P, Mougenot B, Viron B, et al. Nephropathy associated with infection by human immunodeficiency virus: a report on 11 cases including 6 treated with zidovudine. Nephron 62: 434–440, 1992PubMedCrossRefGoogle Scholar
  16. Morse GD, Shelton MJ, O’Donnell AM. Comparative pharmacokinetics of antiviral nucleoside analogues. Clinical Pharmacokinetics 24: 101–123, 1993PubMedCrossRefGoogle Scholar
  17. Pachon J, Cisneros JM, Castillo JR, Garcia-Pesquera F, Canas E, et al. Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis. AIDS 6: 827–830, 1992PubMedCrossRefGoogle Scholar
  18. Paoli I, Dave M, Cohen B. Pharmacodynamics of zidovudine in patients with end-stage renal disease [Letter]. New England Journal of Medicine 326: 839–840, 1992PubMedCrossRefGoogle Scholar
  19. Rachlis A, Fanning MM. Zidovudine toxicity. Clinical features and management. Drug Safety 8: 312–320, 1993PubMedCrossRefGoogle Scholar
  20. Singlas E, Pioger J-C, Taburet A-M, Colin J-N, Fillastre J-P. Zidovudine disposition in patients with severe renal impairment: influence of haemodialysis. Clinical Pharmacology and Therapeutics 46: 190–197, 1989PubMedCrossRefGoogle Scholar
  21. Spivak JL, Barnes DC, Fuchs E, Quinn TC. Serum immunoreactive erythropoietin in HIV-infected patients. Journal of the American Medical Association 261: 3104–3107, 1989PubMedCrossRefGoogle Scholar
  22. Stagg MP, Cretton EM, Kidd L, Diasio RB, Sommadossi J-P. Clinical pharmacokinetics of 3′-azido-3′deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine. Clinical Pharmacology and Therapeutics 51: 668–676, 1992PubMedCrossRefGoogle Scholar
  23. Stellbrink H-J, Averdunk R, Stoehr A, Albrecht H. Zidovudine half-life in haemodialysis patients [Letter]. AIDS 7: 141–142, 1993PubMedCrossRefGoogle Scholar
  24. Tadepalli SM, Puckett L, Jeal S, Kanis L, Quinn RP. Differential assay of zidovudine and its glucuronide metabolite in serum and urine with a radioimmunoassay kit. Clinical Chemistry 36: 897–900, 1990PubMedGoogle Scholar
  25. Touchette MA, Slaughter RL. The effect of renal failure on hepatic drug clearance. DICP, The Annals of Pharmacotherapy 25: 1214–1224, 1991Google Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • D. M. Burger
    • 1
  • P. L. Meenhorst
    • 2
  • J. W. Mulder
    • 2
  • C. H. W. Koks
    • 1
  • A. Bult
    • 3
  • J. H. Beijnen
    • 1
  1. 1.Department of PharmacySlotervaart HospitalAmsterdamThe Netherlands
  2. 2.Department of Internal MedicineSlotervaart HospitalAmsterdamThe Netherlands
  3. 3.Utrecht UniversityUtrechtThe Netherlands

Personalised recommendations